



March 08, 2023

To,

**BSE Limited** 

Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. **National Stock Exchange of India Limited** 

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

**Scrip code**: 512529

Symbol: SEQUENT

Subject: Update on acquisition of Tineta Pharma Private Limited

Dear Sir/ Madam,

We refer to our announcement on November 07, 2022, regarding acquisition of 100% stake in Tineta Pharma Private limited ('Tineta') by the Company, it is hereby informed that the transaction contemplated under the Share Purchase Agreement has not been materialized. Therefore, the Company will not acquire Tineta and the Share Purchase Agreement entered by the Company with Tineta and its Promoters on November 07, 2022 stands terminated.

Yours sincerely,
For Sequent Scientific Limited

Krunal Shah
Company Secretary & Compliance Officer

Website: http://www.sequent.in | Email Id: investorrelations@sequent.in